天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01779 天辰生物-B

已收盘 10-21 16:08:18

69.150

-4.650

-6.30%

最高77.500	最低68.500	成交量15.55万
今开73.800	昨收73.800	日振幅12.20%
总市值52.78亿	流通市值51.90亿	总股本7,632万
成交额1,117万	换手率0.21%	流通股本7,506万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"天辰生物-B","latestPrice":69.15,"timestamp":1792570098766,"preClose":73.8,"halted":0,"volume":155500,"delay":0,"changeRate":-0.0630081300813007,"floatShares":75059200,"shares":76322100,"eps":-3.099834,"marketStatus":"已收盘","change":-4.65,"latestTime":"10-21 16:08:18","open":73.8,"high":77.5,"low":68.5,"amount":11174810,"amplitude":0.121951,"askPrice":69.2,"askSize":100,"bidPrice":69.15,"bidSize":3650,"shortable":0,"etf":0,"ttmEps":-3.261,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792632600000},"marketStatusCode":5,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":73.8,"openAndCloseTimeList":[[1792546200000,1792555200000],[1792558800000,1792569600000]],"volumeRatio":0.519494,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01779","defaultTab":"news","newsList":[{"id":"2677292106","title":"天辰生物-B(01779)：LP-005用于治疗PNH的中国II期临床试验顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677292106","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677292106?lang=zh_cn&edition=full","pubTime":"2026-10-21 16:38","pubTimestamp":1792571908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-005于中国进行的II期临床试验的顶线数据已读出。LP-005的潜在适应症包括PNH等补体介导自身免疫性疾病、补体介导肾脏疾病及牙周炎。II期临床试验共入组30名PNH患者，其中27名患者完成了24周治疗。LP-005整体展现出良好的安全性及耐受性特征。该等结果支持进一步推进LP-005的临床开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","IBBJ","PSYK","MDTX","01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164614845","title":"天辰生物-B披露LP-005治疗PNH中国II期临床试验顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1164614845","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164614845?lang=zh_cn&edition=full","pubTime":"2026-10-21 16:35","pubTimestamp":1792571752,"startTime":"0","endTime":"0","summary":"香港，2026年10月21日，天辰生物-B发布自愿性公告称，公司自主研发的双功能抗体融合蛋白LP-005用于治疗阵发性睡眠性血红蛋白尿症的中国II期临床试验已完成顶线数据读取，结果显示该药物在疗效和安全性方面表现亮眼。试验共入组30名PNH患者，其中27名完成了24周治疗。天辰生物-B亦提醒投资者，LP-005能否最终获批上市仍存在不确定性，投资者应审慎决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192799737","title":"天辰生物-B（01779）拟于10月30日召开临时股东会审议章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1192799737","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192799737?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:05","pubTimestamp":1791551125,"startTime":"0","endTime":"0","summary":"天辰生物-B公告，公司已发出临时股东会通知，会议定于2026年10月30日16:00在中国上海市浦东新区张江高科技园区祖冲之路887号88号楼302室举行。\\n\\n关键信息：\\n1. 股权登记日：2026年10月30日；H股过户登记将于10月27日至10月30日暂停办理，H股未登记股东须于10月26日16:30前完成过户手续。\\n\\n符合资格的股东可亲自出席或委托代表参会并投票，交通及食宿费用自理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161325090","title":"天辰生物-B（01779）拟修订公司章程　反映超额配股权悉数行使后的股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1161325090","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161325090?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:00","pubTimestamp":1791550832,"startTime":"0","endTime":"0","summary":"2026年10月9日，天辰生物医药（苏州）股份有限公司公告称，董事会建议对公司章程进行修订，以反映首发上市后超额配股权悉数行使后带来的注册资本及股本结构变动，并使相关条款符合最新适用的国内法律法规。超额配股权已全部行使，公司因此额外发行2,128,950股H股。上述修订方案将提呈公司即将举行的临时股东大会，以特别决议方式表决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123855528","title":"天辰生物-B 9月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1123855528","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123855528?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:39","pubTimestamp":1791362397,"startTime":"0","endTime":"0","summary":"天辰生物医药(苏州)股份有限公司于2026年10月7日发布截至2026年9月30日的股份变动月报表。报告期内，公司法定/注册股本合计为人民币76,322,100元，整体结构保持稳定。根据公告，天辰生物医药(苏州)股份有限公司在本月内未进行新增发行、股份购回、注销或库存股份变动。公司表示，目前符合香港联合交易所对公众持股量的相关规定和要求，未发生影响公司公众持股比例的情形。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669194606","title":"入通后股价7日跌近30%，何以撑起天辰生物-B(01779)后续股价？","url":"https://stock-news.laohu8.com/highlight/detail?id=2669194606","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669194606?lang=zh_cn&edition=full","pubTime":"2026-09-22 09:05","pubTimestamp":1790039133,"startTime":"0","endTime":"0","summary":"9月7日获纳入港股通名单后，天辰生物-B股价走出了一段明显的下跌行情。9月7日，港股通标的名单正式生效，本轮调整新纳入54只个股，剔除15只。数据显示，9月7日，南向净买入天辰生物约1.08亿港元，占当日总成交额约67%，但天辰生物当天股价仍大跌10.31%。从盘面来看，在连续7个交易日急跌之后，天辰生物股价终于迎来了三日反弹行情。但即便如此，天辰生物9月18日的成交量表现仍远低于9月7日的128.77万股和9月8日的81.78万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106859908","title":"天辰生物-B（01779）公布最新董事会及委员会架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1106859908","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106859908?lang=zh_cn&edition=full","pubTime":"2026-09-10 20:55","pubTimestamp":1789044931,"startTime":"0","endTime":"0","summary":"在董事会下设的三个专门委员会中，各董事的任职情况如下：。公司表示，相关委员会的组成符合监管要求，将继续加强公司治理并提升决策效率。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127028722","title":"天辰生物-B（01779.HK）临时股东大会通过非执行董事委任议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1127028722","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127028722?lang=zh_cn&edition=full","pubTime":"2026-09-10 20:55","pubTimestamp":1789044917,"startTime":"0","endTime":"0","summary":"天辰生物医药（苏州）股份有限公司9月10日公告，于2026年9月10日在中国上海举行的临时股东大会上，通过唯一普通决议案——同意委任薛凯路先生为非执行董事并确定其薪酬。公告显示，截至会议当日，公司已发行股份总数为76,322,100股，其中H股75,059,218股，非上市股份1,262,882股。股东及授权代表共持有36,625,712股股份出席会议，约占已发行股份总数的48.0%。会上所有表决均以投票方式进行，公司香港H股证券登记处卓佳证券登记有限公司及两名股东代表担任监票员。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349184","title":"港股异动 | 天辰生物-B(01779.HK)反弹逾7% 日前进入港股通名单 核心管线产品LP‑003 BLA已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349184","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665349184?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:37","pubTimestamp":1788835028,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111645667","title":"天辰生物-B（01779）被纳入沪深港通合资格证券名单 自2026年9月7日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1111645667","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111645667?lang=zh_cn&edition=full","pubTime":"2026-09-07 22:00","pubTimestamp":1788789628,"startTime":"0","endTime":"0","summary":"天辰生物-B9月7日自愿公告称，根据上海证券交易所于2026年9月4日发布的《关於沪港通下港股通标的调整的通知》及深圳证券交易所于2026年9月7日发布的《关於深港通下的港股通标的证券名单调整的公告》，公司股份已被纳入沪港通及深港通计划下的合资格证券名单，生效日期为2026年9月7日。股份纳入相关名单后，中国内地合资格投资者可透过上海证券交易所及深圳证券交易所直接买卖天辰生物-B在香港联交所上市的股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312527","title":"天辰生物-B(01779)获纳入沪港通及深港通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665312527?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:57","pubTimestamp":1788789421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 公布，根据上海证券交易所于2026年9月 4日发布的《关于沪港通下港股通标的调整的通知》及深圳证券交易所于2026年9月 7日发布的《关于深港通下的港股通标的证券名单调整的公告》，公司已获纳入沪港通及深港通计划下的合资格证券名单，自2026年9月7日起生效。董事会认为，股份获纳入沪港通及深港通交易机制，显示市场对本公司的投资价值及增长前景高度认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120103970","title":"天辰生物-B 8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1120103970","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120103970?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:56","pubTimestamp":1788429386,"startTime":"0","endTime":"0","summary":"天辰生物醫藥(蘇州)股份有限公司于2026年9月3日披露截至2026年8月31日的股份变动月报表。公告显示，公司本月未发生新增股份发行、购回或库存股变化，股本结构保持稳定。具体来看，截至2026年8月31日，公司已发行H股75,059,218股，未上市股份1,262,882股，两项合计76,322,100股；相比上月底无增减变动。本次公告由执行董事谢鸣签署，公司表示将持续严格遵守相关监管规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125997016","title":"天辰生物-B（01779）公布最新董事会及三大专门委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1125997016","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125997016?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:43","pubTimestamp":1788169430,"startTime":"0","endTime":"0","summary":"2026年8月31日，天辰生物醫藥（蘇州）股份有限公司发布公告，披露公司董事会成员构成及各专门委员会的任职情况。董事会下设审计委员会、薪酬委员会及提名委员会，公告列明各董事在三大专门委员会中的职务如下：。公司方面表示，当前董事会架构及专门委员会设置符合公司章程及香港联交所相关规则要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661629604","title":"天辰生物-B(01779.HK)建议实施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661629604","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661629604?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:37","pubTimestamp":1787323025,"startTime":"0","endTime":"0","summary":"格隆汇8月21日丨天辰生物-B(01779.HK)公告，董事会已审议并批准实施H股全流通的建议，即将公司1,262,882股非上市股份转换为公司H股。根据公司章程，H股全流通以及转换及上市毋须获得股东于股东会上的批准。\r\n\r\n　　于本公告日期，公司尚未就H股全流通向中国证监会提交任何备案申请文件。待取得所有相关批准及╱或备案，并已遵守所有适用法律、规则及法规后，该等非上市股份将转换为H股，而公司将向联交所申请该等H股于联交所主板上市及准许买卖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260821/32343568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173336240","title":"天辰生物-B（01779）拟实施1,262,882股H股全流通并调整董事会架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1173336240","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173336240?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:32","pubTimestamp":1787322778,"startTime":"0","endTime":"0","summary":"天辰生物医药（苏州）股份有限公司8月21日发布公告称，董事会已审议通过实施H股全流通方案，并拟同步调整非执行董事人选。天辰生物-B计划将1,262,882股境内未上市股份转换为H股。根据公司章程，此项H股全流通及股份转换上市工作无需股东大会批准。天辰生物-B表示，将按照香港上市规则及相关监管要求，视实施进展及时发布后续公告，提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110705107","title":"天辰生物-B（01779）拟于2026年9月10日召开临时股东会　审议委任薛凯路为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1110705107","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110705107?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:32","pubTimestamp":1787322763,"startTime":"0","endTime":"0","summary":"天辰生物医药（苏州）股份有限公司8月21日在港交所披露临时股东会通告。公司计划于2026年9月10日16时在中国上海市浦东新区张江高科技园区祖冲之路887号88号楼302室召开临时股东会，审议并酌情批准委任薛凯路先生为非执行董事及其薪酬的普通决议案。截至通告日期，天辰生物-B董事会由11名董事组成，包括3名执行董事、4名非执行董事及4名独立非执行董事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661296878","title":"天辰生物-B(01779.HK)拟实施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661296878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661296878?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:18","pubTimestamp":1787321885,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199940194","title":"天辰生物-B（01779）发布2026年中期业绩：加大研发投入，期内亏损1.35亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199940194","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199940194?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:56","pubTimestamp":1787306214,"startTime":"0","endTime":"0","summary":"天辰生物医药（苏州）股份有限公司8月21日公布截至2026年6月30日止六个月未经审计的中期业绩。期内公司尚未产生营业收入，研发及管线推进仍为经营重点。期内亏损及全面亏损总额为1.3481亿元，同比扩大43.1%。其他收入及收益为340.1万元，同比增长286.9%。现金及资产：截至2026年6月30日，现金及现金等价物为9.0376亿元，高于2025年12月31日的9,505.1万元；定期存款为3.0433亿元；受限制现金为229.4万元；以公允价值计量且其变动计入当期损益的金融资产为1,506.5万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661269788","title":"天辰生物-B(01779)发布中期业绩，股东应占亏损1.35亿元 同比增加43.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661269788","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661269788?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:47","pubTimestamp":1787305640,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布截至2026年6月30日止6个月的中期业绩，该集团取得其他收入及收益人民币340.1万元，同比增加3809.2%;母公司拥有人应占亏损1.35亿元，同比增加43.1%;每股亏损2.18元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"天辰生物-B(01779)发布中期业绩，股东应占亏损1.35亿元 同比增加43.1%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661302392","title":"天辰生物-B(01779)：LP-003针对季节性过敏性鼻炎适应症的生物制品许可申请(BLA)已获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2661302392","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661302392?lang=zh_cn&edition=full","pubTime":"2026-08-21 06:21","pubTimestamp":1787264506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对季节性过敏性鼻炎适应症的生物制品许可申请已获中国家药品监督管理局受理。LP-003针对性治疗过敏性疾病，包括季节性过敏性鼻炎、CSU、过敏性哮喘、CRSwNP和食物过敏。LP-003的主要功能是阻断血液和组织中的游离IgE，从而抑制IgE介导的过敏反应的发生。抗IgE疗法已被纳入中国季节性过敏性鼻炎和CSU的诊治指南。LP-003针对花生过敏适应症的IND申请亦已获美国食品药品监督管理局 批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longbio.com","stockEarnings":[{"period":"1week","weight":-0.1777},{"period":"1month","weight":-0.2971},{"period":"3month","weight":-0.1614},{"period":"6month","weight":-0.2317},{"period":"ytd","weight":-0.2317}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"天辰生物医药（苏州）股份有限公司是一家主要从事过敏性及自身免疫性疾病的生物药物自主发现与开发的中国公司。该公司的研发平台主要包括高亲和力抗体发现平台和双功能抗体开发平台。该公司的药物治疗方向主要包括季节性过敏性鼻炎（AR）、慢性自发性荨麻疹（CSU）、过敏性哮喘、食物过敏以及其他过敏性疾病、阵发性睡眠性血红蛋白尿症（PNH）、补体介导肾脏疾病、C3肾小球病（C3G）和狼疮性肾炎（LN）及其他补体相关适应症。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"天辰生物-B","nameEN":"LONGBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天辰生物-B,01779,天辰生物-B股票,天辰生物-B股票老虎,天辰生物-B股票老虎国际,天辰生物-B行情,天辰生物-B股票行情,天辰生物-B股价,天辰生物-B股市,天辰生物-B股票价格,天辰生物-B股票交易,天辰生物-B股票购买,天辰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}